Receptors, Antigen, T-Cell
"Receptors, Antigen, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
Descriptor ID |
D011948
|
MeSH Number(s) |
D12.776.543.750.705.816.824
|
Concept/Terms |
Receptors, Antigen, T-Cell- Receptors, Antigen, T-Cell
- T-Cell Antigen Receptor
- Antigen Receptor, T-Cell
- Receptor, T-Cell Antigen
- T Cell Antigen Receptor
- T-Cell Receptors
- Receptors, T-Cell
- T Cell Receptors
- T-Cell Receptor
- Receptor, T-Cell
- T Cell Receptor
- Receptors, T-Cell Antigen
- Receptors, T Cell Antigen
- T-Cell Antigen Receptors
- Antigen Receptors, T-Cell
- Antigen Receptors, T Cell
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Antigen, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Antigen, T-Cell".
- Receptors, Antigen, T-Cell
- Complementarity Determining Regions
- Receptor-CD3 Complex, Antigen, T-Cell
- Receptors, Antigen, T-Cell, alpha-beta
- Receptors, Antigen, T-Cell, gamma-delta
This graph shows the total number of publications written about "Receptors, Antigen, T-Cell" by people in this website by year, and whether "Receptors, Antigen, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 3 | 5 |
1995 | 5 | 2 | 7 |
1996 | 5 | 0 | 5 |
1997 | 0 | 2 | 2 |
1998 | 4 | 7 | 11 |
1999 | 3 | 2 | 5 |
2000 | 2 | 2 | 4 |
2001 | 0 | 3 | 3 |
2002 | 4 | 9 | 13 |
2003 | 2 | 6 | 8 |
2004 | 3 | 7 | 10 |
2005 | 7 | 9 | 16 |
2006 | 8 | 2 | 10 |
2007 | 4 | 6 | 10 |
2008 | 5 | 9 | 14 |
2009 | 8 | 6 | 14 |
2010 | 7 | 8 | 15 |
2011 | 8 | 6 | 14 |
2012 | 4 | 5 | 9 |
2013 | 7 | 11 | 18 |
2014 | 10 | 10 | 20 |
2015 | 7 | 12 | 19 |
2016 | 12 | 9 | 21 |
2017 | 23 | 9 | 32 |
2018 | 18 | 9 | 27 |
2019 | 11 | 16 | 27 |
2020 | 15 | 18 | 33 |
2021 | 19 | 15 | 34 |
2022 | 3 | 30 | 33 |
2023 | 5 | 29 | 34 |
2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T?cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep Med. 2024 Mar 19; 5(3):101469.
-
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-?B Signaling in Patients with Pancreatic Cancer. Clin Cancer Res. 2024 02 01; 30(3):542-553.
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 Mar; 26(3):266-275.
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymphoma. 2024 Mar; 65(3):323-332.
-
GD2-CAR CAR T?cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter. Cancer Cell. 2024 01 08; 42(1):8-10.
-
Autologous engineered T cell receptor therapy in advanced cancer. Hum Vaccin Immunother. 2023 Dec 15; 19(3):2290356.
-
iPSC-derived hypoimmunogenic tissue resident memory T?cells mediate robust anti-tumor activity against cervical cancer. Cell Rep Med. 2023 12 19; 4(12):101327.
-
Management of aggressive lymphoma after CAR T-cell therapy failure. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):364-369.
-
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023 11 28; 7(22):6990-7005.
-
Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.